AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

The stock's fall snapped a two-day winning streak.

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short selling ...

AbbVie’s TV spots say all patients who take the drug, called Ubrelvy, can expect their migraine pain to be eliminated after a ...

DBS analyst Mark Kong CFA has maintained their neutral stance on ABBV stock, giving a Hold rating on September 3. Mark Kong CFA has given his ...